Algorithms reflecting the authors’ experience treating children in CML-CP once failure or suboptimal response is detected by regular monitoring of the BCR-ABL1 transcript ratio. (A) First-line treatment with imatinib; (B) first-line treatment with a 2G-TKI (either dasatinib or nilotinib). IMA, imatinib; KD, kinase domain; SCT, stem cell transplantation.